The Pediatric Phase I/II Therapeutics team is an integrated clinical and translational research program that provides innovative therapies for pediatric and young adult patients with high-risk cancers.

The clinical program incorporates a comprehensive and multidisciplinary approach for patients with metastatic and relapsed cancers. Program activities include new anti-cancer drugs, autologous stem cell transplantation & chemoprotectants, signal transduction inhibitors, cell cycle inhibitors, biological therapies and immunotherapies. Components of the clinical program include:

• Integrated care with referring oncologists
• Seamless patient management with the University of Minnesota Blood & Marrow Transplantation Program.
• Clinical treatment regimens through the Developmental Therapeutics Consortium of the Children's Oncology Group, collaborations with the Pediatric Oncology Branch of the National Institutes of Health, the Blood and Marrow Transplantation Program, and other programs.

The laboratory program is focused on advancing the care of high-risk cancer patients through advanced pharmacogenetics research and development of new therapies to target abnormalities in cancer cells. The program is integrated with Cancer Center research in the development of immune-based cancer therapies, and new technologies in stem cell transplantation.

Advanced subspecialty training is incorporated into the comprehensive Pediatric Hematology, Oncology and Blood and Marrow Transplantation fellowship program of the University of Minnesota Medical School. Visiting research fellowships are also available.

Core Pediatric Oncology/BMT Faculty and Staff

The links below go to physician profiles on the University of Minnesota Physicians Web site. To return to this site, either bookmark this page or use your browser's back button.

Brenda Weigel, M.D.

Joseph P. Neglia, M.D., M.P.H.

K. Scott Baker, M.D.

John Wagner, M.D.

Margy MacMillan, M.D.

Michael Burke, M.D.

Jody Dahl, M.S., R.N., P.N.P.

Tracey Selstad, M.S.W.

Clinic: 612-625-5411

Program Highlights

• One of the oldest and largest advanced pediatric cancer care programs in the United States — a core institution of the national Children's Oncology Group.
• A primary center of the national Children's Oncology Group Phase I/II Chemotherapy Program.
• An integral program of the University of Minnesota Blood and Bone Marrow Transplantation Program.
• Close integration with University of Minnesota Musculoskeletal Tumor Program, Multiple Specialty Pediatric Surgeons, Therapeutic Radiology Department, Pediatric Neurosurgery/Brain Tumor Program, Pediatric Pathology Department, Pediatric Imaging (Radiology) Department, Neurology/Neuropsychology Program, Chemotherapy Pharmacists, Pediatric Nutrition Specialists, Pediatric Rehabilitation Services, Chaplains, Child-Family Life Services and Social Work Services.
• Collaborations with National Cancer Institute/Pediatric Oncology Branch Sarcoma Therapy
• Incorporates an integrated laboratory to improve cure rates by research in pharmacogenetics and development of new therapies for high-risk malignancies.

The Masonic Cancer Center is one of only 41 institutions in the country designated by the National Cancer Institute as a Comprehensive Cancer Center.